IL188350A0 - Il-28 and il 29 truncated cysteine mutants and antivital methods of using same - Google Patents
Il-28 and il 29 truncated cysteine mutants and antivital methods of using sameInfo
- Publication number
- IL188350A0 IL188350A0 IL188350A IL18835007A IL188350A0 IL 188350 A0 IL188350 A0 IL 188350A0 IL 188350 A IL188350 A IL 188350A IL 18835007 A IL18835007 A IL 18835007A IL 188350 A0 IL188350 A0 IL 188350A0
- Authority
- IL
- Israel
- Prior art keywords
- antivital
- methods
- same
- cysteine mutants
- truncated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70090505P | 2005-07-20 | 2005-07-20 | |
| PCT/US2006/028215 WO2007012033A2 (en) | 2005-07-20 | 2006-07-20 | Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL188350A0 true IL188350A0 (en) | 2008-04-13 |
Family
ID=37600989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL188350A IL188350A0 (en) | 2005-07-20 | 2007-12-24 | Il-28 and il 29 truncated cysteine mutants and antivital methods of using same |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20070053933A1 (enExample) |
| EP (1) | EP1912668A2 (enExample) |
| JP (1) | JP2009502803A (enExample) |
| AU (1) | AU2006269908A1 (enExample) |
| CA (1) | CA2616122A1 (enExample) |
| IL (1) | IL188350A0 (enExample) |
| WO (1) | WO2007012033A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| EP1575609A4 (en) | 2002-10-23 | 2010-12-15 | Zymogenetics L L C | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29 |
| EP2251353B1 (en) * | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Homogeneous preparations of IL-29 |
| CA2558829C (en) | 2004-04-02 | 2014-03-11 | Zymogenetics, Inc. | Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| AU2006272937A1 (en) * | 2005-07-20 | 2007-02-01 | Bristol-Myers Squibb Company | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP1912668A2 (en) * | 2005-07-20 | 2008-04-23 | ZymoGenetics, Inc. | Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
| KR20110126726A (ko) * | 2005-10-07 | 2011-11-23 | 화이자 프로덕츠 인코포레이티드 | 개과 동물의 인플루엔자의 치료를 위한 백신 및 방법 |
| RU2496514C2 (ru) * | 2008-06-05 | 2013-10-27 | Займоджинетикс, Инк. | Применение пэгилированных интерферонов типа iii для лечения гепатита с |
| US20100093618A1 (en) * | 2008-10-15 | 2010-04-15 | Quinto Ileana | Polypeptide capable of inhibiting hiv-1 transcription and replication and uses thereof |
| US20110243888A1 (en) * | 2008-11-20 | 2011-10-06 | Sheppard Paul O | Il-29 mutants and uses thereof |
| US20100316604A1 (en) * | 2009-04-21 | 2010-12-16 | Asterion Limited | Interferon lambda fusion polypeptides |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| CN103923209B (zh) * | 2014-05-13 | 2016-06-22 | 北京凯因科技股份有限公司 | 一种Lambda干扰素突变体及聚乙二醇衍生物 |
| CN105085658B (zh) * | 2014-05-14 | 2019-12-24 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体及聚乙二醇衍生物 |
| CN107530338B (zh) | 2015-04-21 | 2020-12-01 | 艾格尔峰生物制药有限公司 | 包含洛那法尼和利托那韦的药物组合物 |
| KR20180110127A (ko) | 2016-02-19 | 2018-10-08 | 아이거 바이오파마슈티컬스 인코포레이티드 | 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료 |
| CN112694526B (zh) * | 2020-05-27 | 2023-01-20 | 杭州先为达生物科技有限公司 | 一种白细胞介素29突变体蛋白 |
| WO2024241086A1 (en) * | 2023-05-24 | 2024-11-28 | Ambrx, Inc. | Pegylated bovine interferon lambda and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US6468776B1 (en) * | 2000-03-03 | 2002-10-22 | Zymogenetics, Inc. | Human serine protease |
| AU2001271786A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Interferon-like protein zcyto21 |
| AU2001271589A1 (en) * | 2000-06-30 | 2002-01-14 | Zymogenetics Inc. | Mammalian secreted proteins |
| US7038032B2 (en) * | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| BR0309401A (pt) * | 2002-04-19 | 2007-02-21 | Zymogenetics Inc | polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo |
| EP1575609A4 (en) * | 2002-10-23 | 2010-12-15 | Zymogenetics L L C | METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29 |
| EP2251353B1 (en) * | 2003-08-07 | 2013-03-06 | ZymoGenetics, Inc. | Homogeneous preparations of IL-29 |
| CA2558829C (en) * | 2004-04-02 | 2014-03-11 | Zymogenetics, Inc. | Methods for treating viral infection using il-28 and il-29 cysteine mutants |
| AU2005266892B2 (en) * | 2004-07-29 | 2011-03-03 | Bristol-Myers Squibb Company | Use of IL-28 and IL-29 to treat cancer and autoimmune disorders |
| AU2006272937A1 (en) * | 2005-07-20 | 2007-02-01 | Bristol-Myers Squibb Company | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP1912668A2 (en) * | 2005-07-20 | 2008-04-23 | ZymoGenetics, Inc. | Il28 and il29 truncated cysteine mutants and antiviral methods of using same |
| EP1931704B1 (en) * | 2005-10-04 | 2010-12-15 | ZymoGenetics, L.L.C. | Production and purification of il-29 |
-
2006
- 2006-07-20 EP EP06787996A patent/EP1912668A2/en not_active Withdrawn
- 2006-07-20 AU AU2006269908A patent/AU2006269908A1/en not_active Abandoned
- 2006-07-20 WO PCT/US2006/028215 patent/WO2007012033A2/en not_active Ceased
- 2006-07-20 JP JP2008522960A patent/JP2009502803A/ja active Pending
- 2006-07-20 CA CA002616122A patent/CA2616122A1/en not_active Abandoned
- 2006-07-20 US US11/458,945 patent/US20070053933A1/en not_active Abandoned
-
2007
- 2007-12-24 IL IL188350A patent/IL188350A0/en unknown
-
2011
- 2011-03-07 US US13/042,083 patent/US20110182852A1/en not_active Abandoned
- 2011-12-20 US US13/331,000 patent/US20120114590A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1912668A2 (en) | 2008-04-23 |
| JP2009502803A (ja) | 2009-01-29 |
| AU2006269908A1 (en) | 2007-01-25 |
| US20070053933A1 (en) | 2007-03-08 |
| US20110182852A1 (en) | 2011-07-28 |
| WO2007012033A2 (en) | 2007-01-25 |
| CA2616122A1 (en) | 2007-01-25 |
| WO2007012033A9 (en) | 2007-04-05 |
| WO2007012033A3 (en) | 2008-04-24 |
| US20120114590A1 (en) | 2012-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL188350A0 (en) | Il-28 and il 29 truncated cysteine mutants and antivital methods of using same | |
| EP1546112A4 (en) | IMIDAZOLOPYRIDINE AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| IL172689A0 (en) | Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE | |
| AU2003259735A8 (en) | Small-mer compositions and methods of use | |
| GB0422525D0 (en) | Dermatological compositions and methods | |
| GB0318134D0 (en) | Specimen tip and tip holder assembly | |
| AU2003220205A8 (en) | Ethanol-diesel fuel composition and methods thereof | |
| GB0411940D0 (en) | Methods and compositions | |
| IL182734A0 (en) | 4-aminotetracyclines and methods of use thereof | |
| EP1701725A4 (en) | PROCESS AND COMPOSITIONS | |
| EP1932882A4 (en) | HARDENING COMPOSITION AND OPTICAL ELEMENT THEREFOR | |
| AU2003270626A1 (en) | Magnetically modified electrodes as well as methods of making and using the same | |
| EP1497270A4 (en) | AMID COMPOUNDS AND METHOD FOR THEIR USE | |
| IL177640A0 (en) | Methods for treating viral infection using il-28 and il-29 cysteine mutants | |
| PL375355A1 (en) | Novel lipases and uses thereof | |
| EP1726008A4 (en) | BIS-PROPYLAMINE ANALOG AND COMPOSITION | |
| PL1677949T3 (pl) | Kompozycje przeciw przywieraniu i sposoby ich wybierania | |
| GB0208081D0 (en) | Skincare compositions and methods | |
| AU2003299441A8 (en) | Nf-hev compositions and methods of use | |
| GB2393963B (en) | Sliding composition and sliding member | |
| GB0416252D0 (en) | Cosmetic method and composition | |
| IL184062A0 (en) | Visco-supplement composition and methods | |
| EP1684771A4 (en) | COMPOSITION AND METHOD | |
| EP1888779A4 (en) | METHOD FOR THE ANALYSIS OF POLYMORPHISMS AND USES THEREOF | |
| IL192143A0 (en) | Alumina particles and methods of making the same |